SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

2/9/23 8:23:46 AM ET

Specialty Insurers

Finance

Get the next $LIFE alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.12 ATYR PHARMA INC COMMON STOCK Cusip #002120202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #002120202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,351,407 Item 6: 0 Item 7: 4,351,407 Item 8: 0 Item 9: 4,351,407 Item 11: 14.999% Item 12: HC Cusip #002120202 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,351,407 Item 8: 0 Item 9: 4,351,407 Item 11: 14.999% Item 12: IN Item 1(a). Name of Issuer: ATYR PHARMA INC Item 1(b). Address of Issuer's Principal Executive Offices: 3545 John Hopkins Court, Suite #250 San Diego , CA 92121 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 002120202 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,351,407 (b) Percent of Class: 14.999% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,351,407 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ATYR PHARMA INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of ATYR PHARMA INC, amounted to 1,577,641 shares or 5.438% of the total outstanding COMMON STOCK at December 30, 2022. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ATYR PHARMA INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $LIFE alert in real time by email

Recent Analyst Ratings for

$LIFE

Date	Price Target	Rating	Analyst
2/23/2026	$33.00	Buy	Goldman
2/23/2026	$18.00	Outperform	Robert W. Baird
2/23/2026	$21.00	Mkt Outperform	Citizens
2/23/2026	$20.00	Overweight	Barclays
2/23/2026	$23.00	Buy	Deutsche Bank
2/23/2026	$13.00	Overweight	Analyst
2/23/2026	$15.00	Buy	Citigroup
2/23/2026		Outperform	William Blair

More analyst ratings

SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

2/9/23 8:23:46 AM ET

$LIFE

Specialty Insurers

Finance

Get the next $LIFE alert in real time by email

Recent Analyst Ratings for

$LIFE

Date	Price Target	Rating	Analyst
2/23/2026	$33.00	Buy	Goldman
2/23/2026	$18.00	Outperform	Robert W. Baird
2/23/2026	$21.00	Mkt Outperform	Citizens
2/23/2026	$20.00	Overweight	Barclays
2/23/2026	$23.00	Buy	Deutsche Bank
2/23/2026	$13.00	Overweight	Analyst
2/23/2026	$15.00	Buy	Citigroup
2/23/2026		Outperform	William Blair

More analyst ratings

SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$LIFE

SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$LIFE

$LIFE
Insider Purchases

Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

$LIFE
SEC Filings

SEC Form SCHEDULE 13G filed by Ethos Technologies Inc.

SEC Form 144 filed by Ethos Technologies Inc.

SEC Form 144 filed by Ethos Technologies Inc.

$LIFE
Analyst Ratings

Goldman initiated coverage on Ethos Technologies with a new price target

Robert W. Baird initiated coverage on Ethos Technologies with a new price target

Citizens initiated coverage on Ethos Technologies with a new price target

$LIFE
Press Releases

Ethos and North American Expand Their Indexed Universal Life Product Offering to include Children

Ethos Partners with Amanda Kloots to Help Families Take Control of the One Thing They Can

Ethos to Announce Second Quarter 2026 Financial Results on August 3, 2026

$LIFE
Insider Trading

President Wang Lingke was granted 900,000 shares, increasing direct ownership by 129% to 1,595,302 units (SEC Form 4)

CEO and Secretary Colis Peter George was granted 900,000 shares, increasing direct ownership by 129% to 1,595,302 units (SEC Form 4)

President Wang Lingke sold $1,024,561 worth of shares (46,349 units at $22.11), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) (withholding tax)

$LIFE
Financials

Ethos to Announce Second Quarter 2026 Financial Results on August 3, 2026

Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

$LIFE
Large Ownership Changes